Labcorp receives fda de novo marketing authorization for pgdx elio™ plasma focus dx

Pgdx elio™ plasma focus dx is the industry's first and only kitted, pan-solid tumor liquid biopsy test that enables tumor mutation profiling – all from a simple blood draw burlington, n.c., aug. 2, 2024 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, announced today it has received de novo marketing authorization from the u.s. food and drug administration (fda) for pgdx elio™ plasma focus dx – the industry's first and only kitted, pan-solid tumor liquid biopsy test.
LH Ratings Summary
LH Quant Ranking